<DOC>
	<DOCNO>NCT02530762</DOCNO>
	<brief_summary>The study assess gastrointestinal tolerability single serve novel dietary fiber three different dose level generally healthy men woman . Double-blind control , cross-over clinical trial negative ( added fiber ) positive control . Single dose , 24 hour data collection 1 week wash-out cross-overs . 45 randomized , generally healthy men woman , 18-54 , BMI high equal 18.5 small equal 39.99 kg/m2 . Novel dietary fiber ingredient positive control deliver 240 ml beverage .</brief_summary>
	<brief_title>Acute Gastrointestinal Tolerability Following Single Serving Novel Dietary Fiber</brief_title>
	<detailed_description>This randomize , double-blind , crossover study consist one screen visit ( visit 1 , day -7 ) 10 test visit ( day 0 , 1 , 7 , 8 , 14 , 15 , 21 , 22 , 28 , 29 ) . At screen visit ( visit 1 , day -7 ) , subject provide informed consent , medical history clinic visit procedure perform . Subjects meet initial study inclusion/exclusion criterion instruct maintain habitual diet physical activity pattern throughout study period . Subjects also instruct avoid foods/beverages cause Gastrointestinal ( GI ) -distress , well high-fiber food 24 h prior next clinic visit ( visit 2 , day 0 ) . Additional instruction include avoid use non-steroidal anti-inflammatory drug ( NSAIDS ) , antacid , proton pump inhibitor ( PPIs ) , H2 receptor antagonists 24 h prior next clinic visit ( visit 2 , day 0 ) . At visit 2 ( day 0 ) , eligible subject return clinic follow overnight fast ( 9-14 h ) undergo clinic visit procedure . Adverse event ( AEs ) also assess . Eligible subject randomly assign test sequence wherein five test period complete crossover design . Subjects administer one serving assign study product consume in-clinic . Subjects instruct consume study product entirety within 15 min standard breakfast . Subjects dispense daily Bowel Habits Diary , include Bristol Stool Scale , record frequency consistency bowel movement follow 24 h ( = 0 time study product consumption ) . Subjects also dispense 1-day diet record record foods/beverages consume . Subjects instruct record foods/beverages follow 24 h , begin study product consumption ( = 0 h ) . Subjects dismiss clinic instruction avoid foods/ beverage cause GI-distress , well high-fiber food , avoid use non-steroidal anti-inflammatory drug ( NSAIDS ) , antacid , proton pump inhibitor ( PPIs ) , H2 receptor antagonist follow 24 h next clinic visit ( visit 3 , day 1 ) . At visit 3 ( day 1 ) , subject arrive clinic 24 h study product consumption follow overnight fast ( 9-14 h ) . Concomitant medication/supplement use , review inclusion/exclusion , AEs assess subject complete GI Tolerability Questionnaire . Subjects also return 1-day diet record Bowel Habits Diary ; visit schedule ensure entire 24 h period follow study product consumption ( = 0 h ) capture . Prior dismiss clinic , subject remind subsequent study visit instruction , include : fasting compliance ( 9-14 h , water ) ; maintenance usual dietary physical activity practice ; avoid use non-steroidal anti-inflammatory drug ( NSAIDS ) , antacid , proton pump inhibitor ( PPIs ) , H2 receptor antagonists 24 h prior next clinic visit ( visit 4 , day 7 ) ; avoidance foods/beverages may cause GI distress , well high-fiber food 24 h prior , duration subsequent test visit ( visit 4 , day 7 ) ] . Visit 2 procedure replicate visit 4 , 6 , 8 , 10 , separate washout period 7 ± 3 day . In addition , subject receive copy 1-Day Diet Record first test visit ( visit 2 ) ask replicate , closely possible , consumption food avoid foods/ beverage cause GI-distress , well high-fiber food . Visit 3 procedure replicate visit 5 , 7 , 9 , 11 .</detailed_description>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Signs Symptoms , Digestive</mesh_term>
	<criteria>Subject male female , 1854 year age , inclusive . Subject body mass index ( BMI ) ≥18.50 ≤39.99 kg/m2 visit 1 ( day 7 ) weight stable ( ± 4.5 kg ) previous 3 month . Subject judge good health basis medical history . Subject willing maintain habitual diet physical activity pattern , include habitual use study approve medication and/or dietary supplement throughout study period . Subject willing avoid foods/beverages cause GIdistress , well highfiber food 24 h prior , follow , visit 2 , 4 , 6 , 8 , 10 . Subject understands study procedure sign form provide informed consent participate study authorization release relevant protect health information study Investigators . Subject report clinically important GI condition would potentially interfere evaluation study product ( e.g. , inflammatory bowel disease , irritable bowel syndrome , history surgery weight loss , gastroparesis , clinically important lactose intolerance ) . History presence clinically important endocrine ( include type 1 2 diabetes mellitus ) , cardiovascular , pulmonary , biliary , renal , hepatic , pancreatic , neurologic disorder , opinion Investigator , could interfere interpretation study result . Recent history ( within 6 week screen , visit 1 ) constipation ( define &lt; 3 bowel movement per week ) , and/or diarrhea ( define ≥3 loose liquid stools/d ) . Recent ( within 6 week screen , visit 1 ) episode acute GI illness nausea , vomit diarrhea . Daily use nonsteroidal antiinflammatory drug ( NSAIDS ) . Daily use antacid , proton pump inhibitor , H2 blocker . Recent use antibiotic ( within 3 month visit 2 , day 0 ) . Use medication ( overthecounter prescription ) dietary supplement ( within 3 week visit 2 , day 0 ) know influence GI function constipation medication supplement ( include laxative , enema , fiber supplement and/or suppository ) ; antidiarrheal agent ; antispasmodic ; prebiotic probiotic supplement . Extreme dietary habit , include limited vegetarian diet intentional consumption high fiber diet . Known allergy sensitivity food ingredient : soy , dairy ( milk ) , wheat , egg , peanut , tree nut , fin fish crustacean . Uncontrolled hypertension ( systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥100 mm Hg visit 1 , day 7 ) . One retest allow separate day prior visit 2 ( day 0 ) , subject whose blood pressure exceed either cut point visit 1 , judgment Investigator . History cancer prior two year , except nonmelanoma skin cancer . Any major trauma surgical event within 2 month visit 2 , day 0 . Females pregnant , plan pregnant study period , lactate , woman childbearing potential unwilling commit use medically approve form contraception throughout study period . The method birth control must record source documentation . Exposure nonregistered drug product within 30 day prior screen visit . Recent history ( within 12 month visit 1 ) strong potential alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1½ oz distil spirit ) . Recent history ( within 2 month visit 1 ) use tobaccocontaining product . Individual condition Investigator believe would interfere ability provide inform consent , comply study protocol , confound interpretation study result put subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Gastrointestinal tolerability</keyword>
	<keyword>dietary fiber</keyword>
	<keyword>clinical trial</keyword>
	<keyword>healthy subject</keyword>
</DOC>